Lung, Phase I
First in Human Study of AZD9592 in Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Frederick Wilson, MD, PhD
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- John Glendening
- Katelyn Scott
- Laura Van Metre Baum, MD, MPH
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cecchini, MD
- Roy S. Herbst, MD, PhD
- Sara Anastasio, RN
- Scott Gettinger, MD
- So Yeon Kim, MD
- Stacey Stein, MD
- Teresa White
- Vanna Dest
- Last Updated08/02/2024
- Study HIC#2000036026